Showing results (141-150 of 194) with videos related to

Sort By:
Pageof 20
JAMA Network Open|July 7, 2026
Patient-Centered Approach to Surgical Prevention of Ovarian Cancer: A Nonrandomized Clinical TrialKaren H Lu, Barbara M Norquist, Gary B Chisholm, et al.
Nature Communications|May 12, 2018
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistanceStephen J Pettitt, Dragomir B Krastev, Inger Brandsma, et al.
Gynecologic Oncology|December 15, 2021
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 studyElizabeth M Swisher, Carol Aghajanian, David M O'Malley, et al.
Nucleic Acids Research|October 16, 2025
Codon specific readthrough as a mechanism of BRCA2 restoration in acquired PARP inhibitor and chemotherapy resistanceCordelia D McGehee, X Wei Meng, Xinyan Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2017
Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group StudyBarbara M Norquist, Mark F Brady, Maria I Harrell, et al.
Gynecologic Oncology|October 23, 2022
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinomaDavid M O'Malley, Amit M Oza, Domenica Lorusso, et al.
Molecular Oncology|February 25, 2014
Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenograftsMonique D Topp, Lynne Hartley, Michele Cook, et al.
Nature Communications|July 16, 2025
Comprehensive RAD51C ovarian cancer variant analysis uncouples homologous recombination and replicative functionsHayley L Rein, Yashpal Rawal, Anna L Palovcak-Lightbourn, et al.
The Lancet. Oncology|January 9, 2023
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trialEve Rodler, Priyanka Sharma, William E Barlow, et al.
Gynecologic Oncology|October 4, 2021
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancerElizabeth M Swisher, Rebecca S Kristeleit, Amit M Oza, et al.
Pageof 20